<div id="readability-page-1"><p>Allianz SE lessened its holdings in shares of  Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 5.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 94,623 shares of the biopharmaceutical company's stock after selling 5,501 shares during the quarter. Allianz SE's holdings in Bristol Myers Squibb were worth $4,380,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Bristol Myers Squibb</strong> alerts:</span></p></div><ul><li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li></ul><p>Several other institutional investors also recently modified their holdings of the stock. Trifecta Capital Advisors LLC bought a new position in shares of  Bristol Myers Squibb in the 2nd quarter worth $25,000.  REAP Financial Group LLC grew its position in  Bristol Myers Squibb by 202.8% in the second quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 428 shares in the last quarter.  Accent Capital Management LLC bought a new position in  Bristol Myers Squibb in the first quarter valued at $33,000.  CBIZ Investment Advisory Services LLC increased its stake in  Bristol Myers Squibb by 66.0% in the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 231 shares during the last quarter.  Finally, GKV Capital Management Co. Inc. purchased a new stake in  Bristol Myers Squibb during the first quarter valued at about $36,000. 76.41% of the stock is currently owned by institutional investors. </p><h2>Insider Transactions at Bristol Myers Squibb</h2><p>In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the company's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the transaction, the executive vice president directly owned 167,379 shares in the company, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Insiders own  0.09% of the company's stock. </p><h2>Bristol Myers Squibb Stock Down 0.9%</h2><ul><li>MarketBeat Week in Review – 02/03 - 02/07</li></ul><p>NYSE BMY opened at $48.64 on Friday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33. The stock has a market capitalization of $99.02 billion, a PE ratio of 19.61, a PEG ratio of 2.23 and a beta of 0.33. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. The business's 50-day moving average is $45.35 and its 200 day moving average is $46.71. </p><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating analysts' consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The business had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. During the same quarter in the prior year, the company posted $1.80 EPS. Bristol Myers Squibb's quarterly revenue was up 2.8% compared to the same quarter last year.  Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Sell-side analysts forecast that  Bristol Myers Squibb Company will post 6.74 earnings per share for the current year. </p><h2>Bristol Myers Squibb Dividend Announcement</h2><ul><li>Weak Guidance from Bristol-Myers Could Be Creating an Opportunity</li></ul><p>The business also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd were given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.1%. The ex-dividend date of this dividend was Friday, October 3rd. Bristol Myers Squibb's payout ratio is presently 83.78%. </p><h2>Analysts Set New Price Targets</h2><p>Several brokerages have recently commented on BMY. Sanford C. Bernstein  reiterated a &#34;market perform&#34; rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Weiss Ratings  reaffirmed a &#34;hold (c-)&#34; rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Morgan Stanley  reissued a &#34;hold&#34; rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Daiwa America lowered shares of Bristol Myers Squibb from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, August 5th. Finally, Daiwa Capital Markets lowered Bristol Myers Squibb from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and set a $42.00 price target on the stock. in a research report on Tuesday, August 5th. Four research analysts have rated the stock with a Buy rating and fifteen have issued  a Hold rating to the company. According to MarketBeat.com, Bristol Myers Squibb  has an average rating of &#34;Hold&#34; and an average target price of $54.58.</p><p><b>Read Our Latest Analysis on BMY</b></p><h2>About Bristol Myers Squibb</h2> (Free Report)<p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Bristol Myers Squibb</li><li>What is a buyback in stocks? A comprehensive guide for investors</li><li>dLocal Falls Despite Blowout Q3 Results—What Investors Are Missing</li><li>P/E Ratio Calculation: How to Assess Stocks</li><li>Ondas Holdings Signals a Rebound as Drone Demand Soars</li><li>What Makes a Stock a Good Dividend Stock?</li><li>Disney’s 2026 Outlook Brightens Under Iger's Magic Touch</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ALIZY

<p>Allianz SE reduced its holdings in Bristol Myers Squibb by 5.5% in Q2, owning 94,623 shares worth $4.38 million. Other institutional investors also adjusted their positions. Bristol Myers Squibb's stock opened at $48.64, with a market cap of $99.02 billion. The company reported Q3 earnings of $1.63 per share, beating estimates, and announced a quarterly dividend of $0.62 per share. Analysts have set new price targets, with mixed ratings from brokerages.</p>

Allianz SE Lowers Position in Bristol Myers Squibb Company $BMY